Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 6/20 | 0.59 |
| ▸ | AXL | P30530 | 2/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.52 |
| ▸ | IGF1R | P08069 | 2/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.52 |
| ▸ | IKBKB | O14920 | 1/20 | 0.52 |
| ▸ | CHUK | O15111 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | PAK4 | O96013 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | PRKACA | P17612 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | LTK | P29376 | 1/20 | 0.52 |
| ▸ | GRK5 | P34947 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30788412 | 1.00 | PRKCI (0.59) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL22493764 | 0.98 | PRKCI (0.57) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL29802760 | 0.98 | PRKCI (0.57) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL2240671 | 0.77 | AURKB (0.71) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL22799623 | 0.77 | PRKCI (0.57) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL858771 | 0.74 | PRKCI (0.59) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL99690 | 0.74 | PRKCI (1.00) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL1176829 | 0.74 | PRKCI (0.59) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL306661 | 0.74 | PRKCI (0.59) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL91443 | 0.74 | PRKCI (0.59) | PRKCIAXLAURKBJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2025-02-27 | — | — | US | disclosed |
| CN-114981268-B | Pyrimidine-4 (3H) -ketone heterocyclic compound, preparation method and application thereof in medicine | 北京诺诚健华医药科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-113874363-B | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-114341124-B | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-03-28 | — | — | US | disclosed |
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-01-30 | — | — | US | disclosed |
| CN-111433205-B | Polycyclic compounds as allosteric SHP2 inhibitors | 锐新医药公司 | 2024-01-19 | — | — | CN | disclosed |
| EP-3724189-B1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| US-20200407372-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2020-12-31 | — | — | US | disclosed |
| EP-3753941-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Blueray Biopharma Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| EP-3724189-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111433205-A | Polycyclic compounds as allosteric SHP2 inhibitors | 锐新医药公司 | 2020-07-17 | — | — | CN | disclosed |
| WO-2020081848-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020081848-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2019118909-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | PRKCI 210/4885AXL 851/4885AURKB 1933/4885 |
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | PRKCI 217/4885AXL 793/4885AURKB 1967/4885 |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PTP4A1, PPP5C | PRKCI 186/4885AXL 915/4885AURKB 1822/4885 |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | PRKCI 217/4885AXL 793/4885AURKB 1967/4885 |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPRJ | PRKCI 175/4885AXL 477/4885AURKB 2080/4885 |
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | PRKCI 217/4885AXL 793/4885AURKB 1967/4885 |
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | PTPN11, PPM1F, PTPRF | PRKCI 790/4885AXL 947/4885AURKB 2779/4885 |
| US-20200407372-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPRJ | PRKCI 175/4885AXL 477/4885AURKB 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.